At Akarna, our mission is to develop
best-­in-­class treatments for
NASH and other chronic liver diseases
NASH is an increasingly common, progressive form of fatty-liver disease that is directly associated with diabetes and obesity, both of which have reached epidemic proportions. At Akarna, our focus is on developing activators (or agonists) of the Farnesoid X Receptor (FXR), a master regulator of metabolic, inflammatory and fibrosis pathways in the liver and a clinically validated target for NASH.